Liver study tests drug processing in impaired patients
NCT ID NCT06052566
First seen Nov 01, 2025 · Last updated Jun 17, 2026 · Updated 32 times
Summary
This study looked at how the drug efinopegdutide behaves in people with moderate to severe liver damage compared to healthy people. A total of 22 adults took a single dose, and researchers measured drug levels and safety. The goal was to understand dosing needs for patients with liver problems, not to treat the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATIC IMPAIRMENT are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Advanced Pharma CR, LLC ( Site 0001)
Miami, Florida, 33147, United States
-
American Research Corporation ( Site 0002)
San Antonio, Texas, 78215, United States
-
Clinical Pharmacology of Miami ( Site 0005)
Miami, Florida, 33014-3616, United States
-
Genesis Clinical Research, LLC ( Site 0006)
Tampa, Florida, 33603, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.